| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-22 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -2.790 | -2.620 | 0.1700 | ||||
| REV | 12.850M | 14.409M | 1.559M |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Esperion Therapeutics (NASDAQ: ESPR) through any online brokerage.
Other companies in Esperion Therapeutics’s space includes: Aerie Pharmaceuticals (NASDAQ:AERI), BioDelivery Sciences Intl (NASDAQ:BDSI), CymaBay Therapeutics (NASDAQ:CBAY), Satsuma Pharmaceuticals (NASDAQ:STSA) and Provention Bio (NASDAQ:PRVB).
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Credit Suisse on January 14, 2022. The analyst firm set a price target for 6.00 expecting ESPR to rise to within 12 months (a possible 47.42% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Esperion Therapeutics (NASDAQ: ESPR) is $4.07 last updated Fri Jan 28 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Esperion Therapeutics.
Esperion Therapeutics’s $Q4 earnings are confirmed for after-market on February 22, 2022.
There is no upcoming split for Esperion Therapeutics.
Esperion Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.